Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharmaceuticals (ASX: TLX,...
HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep-Disordered Breathing Analysis
- FDA 510(k) Clearance (K253390) Validates AI-Based Classification of OSA, CSA, and MSA- Subtype-Specific Respiratory Event Analysis Improves Diagnostic Precision and Supports Next-Generation Digital Biomarker Development- Advanced AI Analysis Using Multi-Channel Physiological Signals, with Additional FDA 510(k) Clearances Planned for Future Releases BOSTON, July 16, 2026 /PRNewswire/ -- HoneyNaps, an AI-based sleep medicine company, today announced that SOMNUM...
Neusoft Selected in KPMG Chinese Rehabilitation and Elderly Care 50 List
SHENYANG, China, July 16, 2026 /PRNewswire/ -- Recently, KPMG Chinese Rehabilitation and Elderly Care 50 List Release and Awards Ceremony was held in Shanghai, China. Neusoft Corporation (SSE:600718) was successfully included in the list, recognized for its end-to-end layout and proven, large-scale implementation across smart elderly care, long-term care, integrated medical-elderly services, home-based care, and urban-level elderly care...
SCIE Study Shows HILO WAVE® Promotes Regenerative Skin Remodeling Without Inflammatory Response
Peer-reviewed preclinical findings validate the regenerative mechanism of HILO WAVE®'s proprietary Dual-HA Technology (DHC®). SEOUL, South Korea, July 16, 2026 /PRNewswire/ -- HILO WAVE®, HIGHER Corporation's proprietary Dual-HA Collagen Booster, has further strengthened its scientific evidence with the publication of a preclinical study in the International Journal of Molecular Sciences (IJMS), an SCIE-indexed international scientific journal. ...
Angel Yeast Showcases Sustainable Protein Innovation at the Growth Asia Summit 2026
SHANGHAI, July 16, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298) showcased its latest yeast protein innovations at the Growth Asia Summit 2026 in Singapore, held from July 8 to 10. On the second day — dedicated to Active Lifestyles, Weight Management, Protein and Healthier Product Innovation — Chen Zhixian, General Manager of...
Novonesis and TurtleTree enter partnership to support commercialization of lactoferrin
COPENHAGEN, Denmark, July 16, 2026 /PRNewswire/ -- Novonesis, a global leader in biosolutions, today announced an agreement with TurtleTree, an innovator in precision fermented ingredients, and the first company to receive a US GRAS "No Objection Letter" for its precision fermented lactoferrin LF+®. Simultaneously, Novonesis is making a minor investment into...
Clinicians Are Adopting AI to Solve the Documentation Crisis, New Global Survey Finds
New report finds 83% of clinicians adopted AI while workplace guidance and governance frameworks were still being developed. NEW YORK, July 16, 2026 /PRNewswire/ -- A survey of 1,823 clinicians across 25 countries has found healthcare professionals are adopting AI faster than health systems can establish the governance needed to support them....
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research team. MELBOURNE, Australia, July 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX,...
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
First patients dosed in OPTIMAL-e Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA study which recently completed patient enrollment. TLX597-Tx is Telix's next generation PSMA-targeting small molecule radioligand therapy...
Seegene: “Virus-Only Testing May Miss Pneumonia-associated Bacterial Respiratory Pathogens” Calls for a Shift to Comprehensive Syndromic PCR Testing
Virus-only testing may miss pneumonia-associated bacterial co-detections in 78% of virus-positive cases, while bacteria-only testing may miss viral co-detections in 88% of cases positive for pneumonia-associated bacterial pathogens Global Million Clinical Study (GMCS) to build clinical evidence supporting comprehensive syndromic PCR testing as a new global testing standard SEOUL,...
